| Zugriffe | |
|---|---|
| KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma | 175 |
| März 2024 | April 2024 | Mai 2024 | Juni 2024 | Juli 2024 | August 2024 | September 2024 | |
|---|---|---|---|---|---|---|---|
| KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma | 2 | 0 | 3 | 2 | 4 | 1 | 3 |
| Zugriffe | |
|---|---|
| 2021_Frost_etal.pdf | 136 |
